Log In/Sign Up Become a Member Submit an Idea
Search

Accelerate Late-Stage R&D

Resource Tag: Accelerate Late-Stage R&D

Tinder for Clinical Trial Enrollment: Two Real-World Patient Matching Platforms

Identifying and enrolling the right patients for clinical trials remains a critical bottleneck, often requiring the screening of up to 100 individuals to find a single eligible candidate.

This challenge is compounded in outpatient settings, where clinicians are often unaware of relevant trials or lack the time to review complex eligibility criteria. As a result, access to potentially life-saving investigational therapies is frequently delayed. Patients themselves often shoulder the burden of researching and identifying suitable trials to share with their physicians.

This webinar presents two real-world examples addressing these challenges:

CureNavi — an AI-first platform spun out of Charité Hospital in Berlin. CureNavi transforms unstructured patient records into actionable insights by:

  • Identifying care gaps by comparing treatments against the latest guidelines.
  • Building a database of trial-ready patients, enabling sponsors and cancer centers to quadruple enrollment in clinical and investigator-initiated trials.

Drug Repurposing Platform — a first-of-its-kind AI system for rare disease patients that:

  • Identifies existing FDA-approved drugs with potential for reuse.
  • Recommends relevant existing and planned clinical trials.

We will demonstrate the AI-first workflow that converts unstructured medical records into a structured database of trial-eligible patients and review the technology stack – OCR, LLMs, and AWS Medical Comprehend – powering these solutions.

For leaders in clinical operations, medical affairs, and R&D strategy, this session offers a practical blueprint for using AI to overcome recruitment barriers and accelerate the delivery of new therapies.

Speakers
  • Ammara Gafoor: Head of Healthcare and Life Science Solutions – Europe, Thoughtworks
  • Gaelle Waltinger: Co-Founder, CureNavi

Establishing Standards for Pharmacovigilance Systems

The PS² project is transforming pharmacovigilance (PV) by creating shared standards for systems and processes, starting with Case Intake. This collaborative effort will reduce costs, eliminate duplication, and improve interoperability across the industry, while enabling faster solution evaluation and greater innovation. By focusing on common requirements and vendor certification, PS² allows pharma companies, suppliers, consultants, and service providers to spend less time on maintenance and more time advancing patient safety.

Pharmacovigilance Systems & Processes Standards (PS2) – Case Intake

Breaking Down Silos. Building Standards. Driving Innovation.

Pharmacovigilance (PV) systems across the pharmaceutical industry share remarkably similar requirements—but suffer from poor interoperability, leading to fragmented solutions, inflated costs, and limited innovation.
 
Join us for a focused webinar introducing the PS2 – Case Intake initiative aimed at defining requirements and integration standards for the pharmacovigilance case intake process. This effort seeks to reduce duplication, foster compatibility across PV technologies, and lay the groundwork for a more agile and cost-effective ecosystem.
 
In this session, we will:

  • Present the project’s background, highlighting the current pain points in PV systems
  • Share the objectives and scope of the initiative, including our approach to stakeholder collaboration
  • Provide a summary of progress to date and outline the next steps
  • Explain how both pharma companies and PV technology vendors can participate and contribute

 
Whether you’re a pharmacovigilance business lead, IT lead, or technology supplier, this webinar will equip you with the insights needed to decide if this initiative aligns with your organization’s strategic interests.
 

Speakers
  • Thomas Kuckuk / Novartis / Head Pharmacovigilance Systems Management
  • James John / AbbVie / Director of IT – Pharmacovigilance Patient Safety
  • Henrik Lynge / Novo Nordisk / VP, Head of Architects & Strategy in Clinical Development
  • John Wise / Pistoia Alliance / Member Services Consultant

Moderation: Marc Graber / Pistoia Alliance / PS2 – Case Intake Project Lead

Transforming R&D with Integrated Human Health Data

Overview

Join the Pistoia Alliance and ZS Associates for a thought-provoking panel discussion on our white paper that envisions a future where seamless integration of research, clinical, and real-world data (RWD) drives groundbreaking advancements in R&D and personalized medicine.

This webinar brings together industry leaders to discuss:

  • The current landscape of health data integration.
  • Barriers—organizational and technical—that must be addressed.
  • Use cases and transformations needed to realize this future.

Key Takeaways

  • Insights from 25+ interviews with C-suite and R&D experts.
  • Strategies for aligning people, processes, technology, and data.
  • Opportunities to collaborate on initiatives to FAIRify data and advance innovation.
  • View and download the report here

Host & Panelists

  • Host – Becky Upton, President, Pistoia Alliance
  • Panelist – Julie Huxley-Jones, Vice President Research. + Manufacturing Technology, Vertex
  • Panelist – Bill Mayo, Senior Vice President Research IT, Bristol Myers Squibb
  • Panelist – Bruce Press, Parter/Principle, ZS Associates

Who Should Attend

This webinar is designed for professionals in R&D, data science, healthcare, and anyone passionate about driving innovation through collaboration.

Let’s build a future where life sciences R&D is faster, more efficient, and focused on delivering better outcomes for patients worldwide.

Patient Listening on Social Media for Patient-Focused Drug Development.

Patients, life science industry and regulatory authorities are united in their goal to reduce the disease burden of patients by closing remaining unmet needs. Patients have, however, not always been systematically and consistently involved in the drug development process. Recognizing this gap, regulatory bodies worldwide have initiated patient-focused drug development (PFDD) initiatives to foster a more systematic involvement of patients in the drug development process and to ensure that outcomes measured in clinical trials are truly relevant to patients and represent significant improvements to their quality of life.

Strategic Priorities Update February 2024

Join us for this inaugural update on the newly formed Strategic Priorities of the Pistoia Alliance, followed by a 30 minutes Q&A with our panelists

Agenda

Dr Becky Upton, President of the Pistoia Alliance

  • Introduction

Dr Christian Baber, Chief Portfolio Officer, Pistoia Alliance

  • Strategic Priorities Overview
  • Harnessing AI to Expedite R&D
  • Delivering Data-Driven Value

Thierry Escudier, Portfolio Lead, Pistoia Alliance  

  • Accelerating Use of Real-World Data
  • Sustainability Driven R&D